Last reviewed · How we verify
MRG003
MRG003 is a bispecific antibody that simultaneously engages tumor cells and immune cells to enhance anti-tumor immunity.
MRG003 is a bispecific antibody that simultaneously engages tumor cells and immune cells to enhance anti-tumor immunity. Used for Solid tumors (specific indications in phase 3 trials not fully disclosed in public domain).
At a glance
| Generic name | MRG003 |
|---|---|
| Sponsor | Shanghai Miracogen Inc. |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MRG003 functions as a bispecific antibody designed to bridge tumor-associated antigens with immune effector cells, thereby enhancing T-cell activation and anti-tumor responses. By simultaneously targeting both tumor cells and immune cells, the drug aims to overcome immune evasion mechanisms and improve therapeutic efficacy in solid tumors.
Approved indications
- Solid tumors (specific indications in phase 3 trials not fully disclosed in public domain)
Common side effects
Key clinical trials
- Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer (PHASE2)
- The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study (PHASE2)
- MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (PHASE2)
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma (PHASE2)
- Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma (PHASE2)
- A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (PHASE3)
- MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC (PHASE2)
- Pembrolizumab + MRGOO3 as Neoadjuvant in NPC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MRG003 CI brief — competitive landscape report
- MRG003 updates RSS · CI watch RSS
- Shanghai Miracogen Inc. portfolio CI